Change in number of shares and votes in Alligator Bioscience AB
During March 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...
Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023
Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors Data strongl ...
Alligator Bioscience Announces Publication Highlighting Bispecific Antibodies Targeting CD40 and Tumor Antigens in Peer-Reviewed Journal for ImmunoTherapy of Cancer
Article shows CD40 x TAA bispecific antibodies can induce enhanced T cell cross-priming superior to monospecific CD40 antibodies using in vi ...
Alligator Bioscience to Present at 10th Annual Immuno-Oncology Summit, October 12 -14, 2022
Lund, Sweden, October 10, 2022 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announced that Mattias Levin, PhD, Sr Team Ma ...